Clinic
topic on 6 shows · 8 statements across 7 episodes
More or Less 
Masters of Scale 
No Priors 
Top Founders 
the a16z Podcast 
All-In
7 statements about Clinic, every show
Friedberg: Custom Peptide Cancer Therapies Cost $50K at Existing Clinics
“You can pay someone 50,000 dollars to do this for you today. There's a lot of clinics that'll do it, and it's not a special FDA-approved drug. To your point, J. Cal, it's a process. The process is, take the DNA sequence from my cancer, make a protein, put it b…”
Meier: Clinical interest in traditional monoclonal antibodies will decline
“So what we predict will happen is people probably won't be as interested in, in the clinic for things like monoclonal antibodies. These are, you know, antibodies that are hitting, for example, like a specific epitope on a protein.”
Aoun: Physical healthcare clinics are not a venture-backable business model
“And frankly, what we learned is you can make clinics like a reasonable business. They're not really a venture backable business is what we found. These are not like, this is not, you're not going to go find a tech company building clinics everywhere everywhere…”
HBox charges clinics $60 to $79 per patient monthly
“We charge per patient on a per month basis, any way between, depending on the volume of the clinic, any way between 60 to 79 dollars per patient per month.”
Bargetti: Fatura Simples focuses on clinics over SaaS companies
“We are focusing on clinics and the tangent, like the similar kinds of operations, because you see SaaS companies don't, we don't have, we don't really have Differential. A competitive differential.”
Bargetti: Healthcare clinics operate at much higher customer volume than SaaS companies
“And this new, new segment, these clinics, they operate in a much higher volume than a SaaS business for example If you have a SaaS business that have, let's say, 2000 customers, it's a big SaaS business. If you have a clinic that has 2000 customers, it's just …”
Lowe: Preclinical bio assets lack significant value until reaching clinical trials
“That is because in the bio space value is created in these huge technical milestones in the very beginning where a lot of these services are used. These are preclinical assets in which there's really not too much value until you bring a drug candidate into the…”